{"id":"NCT01991860","sponsor":"Acacia Pharma Ltd","briefTitle":"US Phase III Study of APD421 in PONV","officialTitle":"Randomized, Double-blind, Placebo-controlled Phase III Study of APD421 (Amisulpride for IV Injection) as Prophylaxis Against Post-operative Nausea and Vomiting","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-08","primaryCompletion":"2014-01","completion":"2014-01","firstPosted":"2013-11-25","resultsPosted":"2018-09-06","lastUpdate":"2019-02-12"},"enrollment":364,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["PONV"],"interventions":[{"type":"DRUG","name":"APD421- Amisulpride for IV injection","otherNames":["Amisulpride for IV injection"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"APD421","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"A comparison of the efficacy of APD421 and placebo in the prevention of PONV in patients at moderate-to-high risk of PONV.","primaryOutcome":{"measure":"Number of Participants With Complete Response","timeFrame":"24 hours after the end of surgery","effectByArm":[{"arm":"APD421 at 5mg","deltaMin":78,"sd":null},{"arm":"Placebo","deltaMin":54,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.033"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":5},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":176},"commonTop":["Procedural Pain","Hyperglycaemia","Anaemia Postoperative","Hypocalcaemia","Hypoproteinaemia"]}}